Phenotype of CD34+ cells prior to and following drug treatment
Condition . | % CD90+ . | % CD117+ . | % CD38- . | % Lin-* . |
|---|---|---|---|---|
| Primary CD34+ cells† | 26.0 ± 7.5† | 48.0 ± 6.4‡ | 8.7 ± 4.3‡ | 53.0 ± 16.2‡ |
| Cytokines plus sequential 5azaD and TSA | 77.0 ± 3.7 | 65.0 ± 20.0 | 18.3 ± 7.0 | 98.0 ± 0.7 |
Condition . | % CD90+ . | % CD117+ . | % CD38- . | % Lin-* . |
|---|---|---|---|---|
| Primary CD34+ cells† | 26.0 ± 7.5† | 48.0 ± 6.4‡ | 8.7 ± 4.3‡ | 53.0 ± 16.2‡ |
| Cytokines plus sequential 5azaD and TSA | 77.0 ± 3.7 | 65.0 ± 20.0 | 18.3 ± 7.0 | 98.0 ± 0.7 |
The table shows the phenotype of CD34+ cells prior to and after exposure to 5azaD and TSA. Each value represents the mean of 3 experiments ± the standard error of the mean. There was no significant difference between the 2 cell populations as related to the expression of CD38, CD117, and lineage markers.
Lineage-negative represents those cells that do not express phenotypic markers associated with terminally differentiated cells (CD2, CD14, CD15, CD16, CD19, glycophorin A)
There is a significant increase in the percentage of CD90+ in the cytokines and sequential 5azaD- and TSA-treated culture when compared with the primary cells (P < .01, student paired t test)